Injectable HDV Mealtime Insulin for Type 1 Diabetes is under clinical development by Diasome Pharmaceuticals and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Injectable HDV Mealtime Insulin for Type 1 Diabetes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Injectable HDV Mealtime Insulin for Type 1 Diabetes overview
Recombinant peptide (Hepatic directed vesicle insulin) is under development for the treatment of type I diabetes. It is administered through parenteral (injectable) route. It is loaded with hepatic-directed vesicles (HDV) prior to administration. It acts by targeting insulin receptor. The therapeutic candidate is a liver-targeted liposome containing insulin by using hepatic- directed vesicle-insulin technology (HDV insulin technology).
It was also under development for the treatment of type II diabetes.
Diasome Pharmaceuticals overview
Diasome Pharmaceuticals (Diasome) is a pharmaceutical company. It focuses on clinical and commercial development of therapies for diabetes and obesity. The company’s pipeline products include multiple injected and oral formulations of liver targeted insulin’s for both type 1 and type 2 diabetic patients. Diasome’s products include oral HDV insulin, injectable HDV insulin and oral HDV candidates among others. The company’s technology platform Hepatocyte directed vesicle (HDV), a cell targeting system which helps to deliver a wide range of necessary hormones and drugs to the liver. It offers products in the fields of insulin replacement, and hepatic (liver) glucose metabolism. Diasome is headquartered in Cleveland, Ohio, the US.
For a complete picture of Injectable HDV Mealtime Insulin for Type 1 Diabetes’s drug-specific PTSR and LoA scores, buy the report here.